Faeth Therapeutics Inc. (FTH)
NASDAQ: FTHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
FTH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $203.65M
- EPS (TTM)
- -$22.50
- Dividend yield
- None
- 52-week range
- 7.45 – 42.14
- Day range
- 7.85 – 9.13
- Volume / Avg
- 419.09K / 500.25K
- Beta
- —
- Shares outstanding
- 25.84M
52-week range
FTH stock today
Shares of Faeth Therapeutics (FTH) finished lower on Nov 20 at $7.88, a drop of 9.32% or $0.81 per share, versus the S&P 500's 3.70% decline. At this level, FTH sits near the bottom of its 52-week range of $7.45 to $42.14: 81.3% below the high, set on Sep 8, 2026 and 5.8% above the low. FTH is down 26.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 9.6%.
Faeth Therapeutics has posted a net loss over the last twelve months (EPS of -$22.50), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Faeth Therapeutics
Company profileFaeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Anand Parikh Esq., J.D.
- Headquarters
- Rockville, MD
- Employees
- 29
- IPO year
- 2021
- Website
- faeththerapeutics.com
Financial highlights
Full financialsFaeth Therapeutics reported a net loss of $21.1 million, compared with a loss of $30.2 million a year earlier. Diluted earnings per share came in at -$16.72.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-21.09M | $-30.16M | $-34.10M | $-48.59M | $-36.79M |
| EPS (diluted) | $-16.72 | $-24.01 | $-1.22 | $-1.58 | $-1.33 |
Analyst forecast
ForecastConsensus (15 analysts)
strong_buy
Avg. price target
$56.15+612.56%
- Strong buy 3
- Buy 12
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.79 vs $-0.66
- Surprise
- -19.70%
FTH news
All FTH news- Faeth Therapeutics (FTH): Betting On Multi-Node Blockade To Disrupt Cancer GrowthNasdaqFTH, BIO.B
- Sensei Biotherapeutics Announces Phase 2 PIK-201 Topline Results for PIKTOR in Endometrial CancerNasdaq
- Sensei Biotherapeutics, Inc. Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 TrialNasdaq
- Faeth Therapeutics Plummets 45% — Here's What HappenedInvestor's Business Daily
- Faeth Therapeutics reports positive Phase 2 results for endometrial cancer drugInvesting.com
- Sensei Biotherapeutics, Inc. Reports Third Quarter 2026 Financial ResultsNasdaqFTH, LEN.B
- Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational UpdatesBusiness Wire
- Sensei Biotherapeutics, Inc. Appoints Adam Schayowitz to Board of Directors on October 23, 2026Nasdaq
Faeth Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BCYCBicycle Therapeutics plc ADR | 2.90 | -4.92% | $203.27M | vs FTH |
| DRUGBright Minds Biosciences Inc. | 20.40 | -1.45% | $201.23M | vs FTH |
| VNDAVanda Pharmaceuticals Inc. | 3.45 | -6.13% | $208.32M | vs FTH |
| NGENNervGen Pharma Corp. | 1.85 | -3.91% | $198.55M | vs FTH |
| CYPHCypherpunk Technologies Inc. | 1.41 | -18.02% | $210.15M | vs FTH |
| BIOABioAge Labs Inc. | 4.28 | -9.13% | $196.67M | vs FTH |
| YARWYarrow Bioscience Inc. | 12.90 | -9.35% | $196.53M | vs FTH |
| ACIUAC Immune SA | 1.95 | -8.45% | $193.88M | vs FTH |
Indexes, lists and sector
Faeth Therapeutics stock FAQ
What is Faeth Therapeutics's stock price today?
FTH last traded at $7.88 as of Nov 20, 4:00 PM EST, down 9.32% on the day. Prices are delayed at least 15 minutes.
Does Faeth Therapeutics pay a dividend?
No. Faeth Therapeutics does not currently pay a regular cash dividend.
Who is Faeth Therapeutics's CEO?
Mr. Anand Parikh Esq., J.D. is the chief executive officer of Faeth Therapeutics Inc., which has about 29 employees.
Has FTH ever split its stock?
Yes. The most recent FTH stock split was a 1-for-20 split on Jun 17, 2025.
What is the FTH 52-week high?
The 52-week high for FTH is $42.14 and the 52-week low is $7.45. The stock is currently 81.3% below its high.